Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
NabGen
AddedFeb 16, 2024
UpdatedJun 18, 2026
NabGen

NabGen

Angel

NabGen, Inc.: An NC biotech firm developing a universal antibody suppressant to enhance gene therapy effectiveness.

HQ
Durham, NC, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

NabGen, Inc., founded in North Carolina, is a biotech company dedicated to advancing gene therapy by overcoming the challenge of patient-derived anti-drug antibodies. Their core mission is to ensure that all patients can benefit from gene therapy treatments, regardless of pre-existing vector immunity. NabGen's primary product is a universal antibody suppressant platform designed to enable successful administration of AAV-based therapeutics and create opportunities for redosing.

Notable figures associated with NabGen include experts in biotechnology and gene therapy, though specific names are not provided. The company has attracted significant interest from investors focused on innovative healthcare solutions. NabGen's key achievements include developing a platform with broad applications in gene therapy, potentially transforming treatment protocols and improving patient outcomes. Their work has a substantial impact on the field by addressing a critical barrier in gene therapy delivery.

NabGen - Similar Companies

Regenxbio logo

Regenxbio

regenxbio.com

Locanabio logo

Locanabio

Apertura Gene Therapy logo

Apertura Gene Therapy

aperturagtx.com

Exegenesis Bio logo

Exegenesis Bio

exegenesisbio.com

Aavogen logo

Aavogen

aavogen.com

Excepgen logo

Excepgen

excepgen.com

Gensaic logo

Gensaic

gensaic.com

Gennao Bio logo

Gennao Bio

gennao.com

RainBio logo

RainBio

rainbio.us

Nephrogen logo

Nephrogen

Nabla Bio logo

Nabla Bio

nabla.bio

Navrogen logo

Navrogen

navrogen.com

Genascence logo

Genascence

genascence.com

GeneVentiv Therapeutics logo

GeneVentiv Therapeutics

geneventiv.com

ImmunoVec logo

ImmunoVec

immunovec.com

NabGen - Quick Facts

Who are NabGen's competitors?

Companies similar to NabGen include Regenxbio, Locanabio, Apertura Gene Therapy and Exegenesis Bio.

When was NabGen founded?

NabGen was founded in 2019.

Where is NabGen's headquarters located?

NabGen's headquarters is located in Durham, NC, US.

When was NabGen's last funding round?

NabGen's most recent funding round was for $269.6k (USD) in March 2023.

How much has NabGen raised to-date?

As of Mar 30, 2023, NabGen has raised a total of $1.3M (USD).

How many employees does NabGen have?

NabGen has 6 employees as of Feb 5, 2024.

NabGen - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Gene Therapy
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified